.png)
Accelerate recruitment and ‘first patient in’ time
Streamlined user journeys help accelerate time to “first patient in” and get your trial up and running with minimal fuss.
Fully-integrated screening and consent enable faster set-up and enrollment. Our DeTAP atrial fibrillation trial recruited 94% of participants in less than two weeks and maintained an 86% retention rate.1
Powering digital-first clinical research
eConsent
eCOA/ePRO
Telemedecine
Connected devices
Seamless set up and go
Maximise participant sign-ups and minimise dropouts with an uninterrupted screening-to-consent process. Invite participants by email directly from the platform and get them up and running quickly with our easy-to-use, step-by-step onboarding module featuring efficient electronic ID verification.
Comprehensive support for multiple market recruitment strategies
The Huma platform is ready to deploy immediately in 80+ countries across the US, Europe, China, Middle East, Southeast Asia, and more. We’re device and cloud-agnostic for the widest possible global deployment flexibility.
We have the ability to recruit participants globally via sites, central participant hubs and recruitment marketing campaigns.
Regulatory, safety and compliance
MHRA registered Medical Device Class IIb
US Food and Drug Administration Medical Device 510k # K230214
ISO 13485: 2016 certified (Medical Devices: Quality Management Systems)
ISO 27001: 2013 certified
Committed to GDPR compliance
NHS Registration on Data Security and Protection Toolkit
CyberEssentials / CyberEssentials Plus
Sources
Sarraju, A., Seninger, C., Parameswaran, V. et al. Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). npj Digit. Med. 5, 80 (2022). https://doi.org/10.1038/s41746-022-00622-10
